HACKENSACK, N.J., July 18, 2016 /PRNewswire/ -- Champions Oncology,
Inc. (NASDAQ: CSBR), a company engaged in the development and sale
of advanced technology solutions and products to personalize the
development and use of oncology drugs, today announced the
successful completion of its first study in acute myeloid leukemia
(AML). Champions Oncology identified AML as an area of
significant unmet customer need and has been pursuing two
technological approaches for developing AML models in conjunction
with external collaborators. The first approach involves AML
modeling from banked patient samples and the second approach is
co-clinical modeling of small volume patient peripheral blood
draws. Each approach is being developed with sponsorship from
existing customers. Both of these collaborations have
demonstrated scientific success and these technologies are now
being offered commercially to a wider set of customers.
Neal Goodwin, Champions
Oncology's Vice President of Corporate Research Development,
commented, "These AML models engrafted in mice including in the
bone marrow where AML cells are often protected from chemotherapy.
With these two techniques, we are able to model defined patient
cohorts and are establishing the capability to model patients with
AML as they enroll on clinical trials and progress
clinically. Our clientele can perform testing in these
co-clinical models to better identify responsive patient
populations to further target their drug development
strategy. Strong demand for these novel models is expected
because of the lack of animal models available for simulating
patient response in AML."
Joel Ackerman, CEO of Champions
Oncology, commented, "Growing the depth and breadth of our tumor
bank is an important component of our growth plan. We expect
AML to be one of the significant contributors to accelerating
revenue growth and margin in our current fiscal year. These
collaborations demonstrate our ability to combine our advanced
scientific and medical affairs capabilities, operational
excellence, and commercial distribution to introduce new
technologies to our customers."
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's technology
platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune-deficient
mice to create TumorGrafts that preserve the biological
characteristics of the original human tumor in order to determine
the efficacy of a treatment regimen. The company uses this
technology in conjunction with related services to offer solutions
for two customer groups: Personalized Oncology Solutions, in which
results help guide the development of personalized treatment plans,
and Translational Oncology Solutions, in which pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development can lower the cost and increase the speed of developing
new drugs. For more information, please
visit www.championsoncology.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-successfully-delivers-first-aml-study-300299400.html
SOURCE Champions Oncology, Inc.